Oflamed-OZ Tablet contains a combination of Ofloxacin 200 mg and Ornidazole 500 mg, formulated to provide broad-spectrum antimicrobial therapy. Ofloxacin, a fluoroquinolone antibiotic, acts by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby preventing bacterial DNA replication and transcription, which results in bactericidal activity against a wide range of gram-positive and gram-negative pathogens. Ornidazole, a nitroimidazole derivative, exhibits potent antiprotozoal and antibacterial effects by disrupting DNA synthesis in anaerobic bacteria and protozoa. This combination is particularly effective in treating mixed infections involving both aerobic and anaerobic organisms, including gastrointestinal infections, genitourinary tract infections, respiratory tract infections, and skin and soft tissue infections. Oflamed-OZ is indicated for conditions such as bacterial dysentery, amoebiasis, trichomoniasis, and other infections caused by susceptible organisms. The tablet should be administered orally as prescribed by a healthcare professional, with dosage and duration tailored to the severity and type of infection. Caution is advised in patients with a history of hypersensitivity to fluoroquinolones or nitroimidazoles, and monitoring for potential side effects such as gastrointestinal disturbances, CNS effects, and hypersensitivity reactions is recommended. This combination provides an effective therapeutic option for polymicrobial infections requiring dual antimicrobial coverage.